FDA warned Panama-based Cosmenic that its website sells unapproved, misbranded injectable botulinum toxin drugs to U.S. consumers.
What happened
FDA reviewed www.cosmenic.net and found it offered botulinum toxin type A marketed as “NABOTA® (JEUVEAU®) 100u” for sale to U.S. consumers. FDA said the product is an unapproved new drug and its labeling lacks adequate directions for use, making it misbranded. There was no inspection; FDA found the issues through its website review.
What FDA found
The website offered botulinum toxin type A as an unapproved new drug without an FDA-approved application.
Section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]; section 301(d) [21 U.S.C. § 331(d)]The product’s labeling lacks adequate directions for use because it is a prescription drug that a layperson cannot safely use without a licensed practitioner.
Section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5Offering the misbranded drug for sale caused it to be introduced into interstate commerce.
Section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]
What FDA wants
FDA asks Cosmenic to stop offering any unapproved and misbranded drugs to U.S. consumers and to respond in writing within 15 working days with the steps taken and related documentation.
Who should pay attention
- U.S. consumers buying injectable cosmetics online
- clinics and med spas considering foreign botulinum toxin suppliers
- online sellers of foreign drug products
This is a summary. Read the original letter on fda.gov.